BioPhenoMA develops a platform utilizing the TN-cyclon™ method for the high-sensitivity quantification of ultra-trace proteins, essential for understanding biological mechanisms. This technology enables researchers to detect minute protein levels, facilitating advancements in drug discovery and biomedical research.
Funding
$1.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for quantifying ultra-trace proteins often lack the sensitivity needed to fully understand biological mechanisms and advance drug discovery. Detecting minute protein levels remains a significant challenge, hindering progress in biomedical research and the development of new therapeutics.
Solution
BioPhenoMA offers a technology platform based on the TN-cyclon™ method, enabling high-sensitivity quantification of ultra-trace proteins. This platform allows researchers to detect and measure extremely small amounts of proteins, which is essential for analyzing the mechanisms of biological phenomena. By providing this capability, BioPhenoMA supports and accelerates research and development in pharmaceuticals, quasi-drugs, and reagents. The company's vision is to create a world where people and living things can coexist in good health, and its mission is to make this technology accessible to anyone, anywhere.
Target Audience
The primary customers are researchers and developers in the pharmaceutical, quasi-drug, and reagent industries, as well as biomedical researchers seeking to understand biological mechanisms.
Features
- TN-cyclon™ method for high-sensitivity protein quantification
- Quantification services for ultra-trace proteins
- Supports research and development of pharmaceuticals, quasi-drugs, and reagents